IP Library › Assignment 027370/0813
Patent Assignment
Reel/Frame 027370/0813

Assignment of Assignor's Interest

Recorded: 2011-12-13 Received: 2011-12-13 Pages: 31
Assignor
GRACEWAY PHARMACEUTICALS, LLC
Executed: 2011-12-02
Assignee
MEDICIS PHARMACEUTICAL CORPORATION
7720 NORTH DOBSON ROAD, SCOTTSDALE, AZ, 85256, UNITED STATES
Covered Properties (98)
Combination Therapy with Low Dosage Strength Imiquimod and Photodynamic Therapy to Treat Actinic Keratosis
Application: 61/535,276 →
Combination Therapy with Low Dosage Strength Imiquimod and Photodynamic Therapy to Treat Actinic Keratosis
Application: 61/534,876 →
Pump Systems and Methods for Storing and Dispensing a Plurality of Precisely Measured Unit-Doses of Imiquimod Cream
Up to Six Weeks Dosing Regimen for Treating Actinic Keratosis with Pharmaceutical Compositions Formulated with 3.75% Imiquimod
Application: 13/184,579 →
3 x 3 x 3 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75 % IMIQUIMOD
Application: 13/184,556 →
High Dosage Strength Metronidazole Vaginal Gel Formulations and Use Thereof for Treating Bacterial Vaginosis
Application: 61/508,058 →
Method of Treating Actinic Keratosis with 3.75% Imiquimod Cream
Application: 13/182,433 →
2 X 2 X 2 Week Dosing Regimen for Treating Actinic Keratosis with Pharmaceutical Compositions Formulated with 3.75 % Imiquimod
Application: 13/181,499 →
Lower Dosage Strength Pharmaceutical Compositions Forumlated with 3.75% Imiquimod
Application: 13/181,507 →
Lower Dosage Strength Pharmaceutical Compositions Formulated with 2.5% Imiquimod
Application: 13/179,402 →
Up to Six Weeks Treatment Regimen for Treating Actinic Keratosis with Pharmaceutical Compositions Formulated with 2.5% Imiquimod
Application: 13/179,336 →
3 x 3 x 3 WEEK TREATMENT REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 2.5% IMIQUIMOD
Application: 13/179,363 →
2 X 2 X 2 Week Treatment Regimen for Treating Actinic Keratosis with Pharmaceutical Compositions Formulated with 2.5% Imiquimod
Application: 13/179,315 →
1.3% Metronidazole Gel Formulations and Use Thereof for Treating Bacterial Vaginosis
Application: 61/502,285 →
Combination Therapy with Cryosurgery and Low Dosage Strength Imiquimod to Treat Actinic Keratosis
Therapeutic Pyrazolyl Thienopyridines
Application: 13/112,520 →
Pump Systems and Methods for Storing and Dispensing a Plurality of Precisely Measured Unit-Doses of Imiquimod Cream
Application: 12/875,787 →
Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
Application: 61/402,251 →
Pump Systems and Methods for Storing and Dispensing a Plurality of Precisely Measured Unit-Doses of Imiquimod Cream
Application: 61/377,336 →
Pump Systems and Methods for Storing and Dispensing a Plurality of Precisely Measured Unit-Doses of Imiquimod Cream
Application: 61/376,154 →
Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
Application: 61/402,052 →
Pump Systems and Methods for Storing and Reproducibly Dispensing Precisely Measured Unit-Doses of Imiquimod Cream
Application: 61/375,580 →
Pump systems and methods for storing and reproducibly dispensing precisely measured unit-doses of imiquimod cream
Application: 61/401,997 →
Systems and Methods for Storing and Dispensing Unit Doses of Imiquimod Cream
Application: 61/371,137 →
Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis
Application: 61/398,494 →
Combination Therapy with Cryosurgery and Low Dosage Strength Imiquimod to Treat Actinic Keratosis
Application: 61/358,845 →
Phenoxy-Pyrrolidine Derivative and Its Use and Compositions
Application: 12/670,010 →
Lower Dosage Strength Imiquimod Formulations and Short Dosing Regimens for Treating Genital and Perianal Warts
Treatment for basal cell carcinoma
Application: 12/798,356 →
Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
Application: 61/341,721 →
Lower dosage strength imiquimod formulations and short dosing regimens for treating genital warts
Application: 61/341,476 →
Immune Response Modifier Formulations
Application: 12/309,367 →
Lower Dosage Strength Imiquimod Formulations and Shorter Dosing Regimens for Treating Actinic Keratoses
Application: 12/636,613 →
Crystalline Acat Inhibitor
Application: 12/577,993 →
Method for Decreasing Sebum Production
Application: 12/568,763 →
Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
Application: 12/543,434 →
Lower Dosage Strength Imiquimod Formulations and Short Dosing Regimens for Treating Genital Warts
Application: 61/225,202 →
Methods of Improving Skin Quality
Application: 12/425,961 →
Lower dosage strength imiquimod formulations and shorter dosing regimens for treating actinic keratoses
Application: 61/205,145 →
Lower Dosage Strength Imiquimod Formulations and Short Dosing Regimens for Treating Actinic Keratosis
Application: 61/144,731 →
Lower Dosage Strength Imiquimod Formulations and Short Dosing Regimens for Treating Actinic Keratosis
Application: 61/139,536 →
Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis with Shorter Durations of Imiquimod Therapy
Application: 61/090,132 →
Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
Application: 61/089,887 →
Process for Preparing 2-Methyl-1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine
Application: 11/794,584 →
Method of Treating Actinic Keratosis
Application: 11/886,204 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 12/054,357 →
Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis with Shorter Durations of Imiquimod Therapy
Application: 12/028,771 →
Treatment for Basal Cell Carcinoma
Application: 12/008,961 →
Intermediates for Imidazonaphthyridines
Application: 11/999,602 →
Therapeutic Pyrazolyl Thienopyridines
Application: 11/871,311 →
Method and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,887 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,891 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,875 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,838 →
Method and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,882 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,870 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,876 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,889 →
Method and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,850 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,890 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,846 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,830 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,892 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,885 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,815 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,881 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,871 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,873 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,811 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,844 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,805 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,817 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,879 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,835 →
Methods and Packages to Enhance Safety When Using Imiquimod to Treat Children Diagnosed with Skin Disorders
Application: 60/896,792 →
Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of lmiquimod therapy
Application: 60/900,550 →
Therapeutic pyrazolyl thienopyridines
Application: 60/851,982 →
PACKAGING FOR 1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-c] QUINOLIN-4-AMINE-CONTAINING FORMULATION
Application: 11/530,935 →
Immune Response Modifier Formulations
Application: 60/807,669 →
Crystalline Acat Inhibitor
Application: 11/354,486 →
Intermediates for Imidazonaphthyridines
Application: 11/276,074 →
Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine-containing formulation
Application: 60/717,483 →
Imidazonaphthyridines
Application: 11/188,418 →
Method of treating actinic keratosis
Application: 60/661,661 →
Crystalline ACAT inhibitor
Application: 60/655,758 →
Urea Substituted Imidazoquinolines
Application: 11/038,434 →
Polymorphs of 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate
Application: 60/641,129 →
Imidazonaphthyridines
Application: 11/004,674 →
Process for Preparing Imidazoquinolinamines
Application: 10/974,258 →
Method for Decreasing Sebum Production
Application: 10/958,306 →
Imidazonaphthyridines
Application: 10/824,232 →
Treatment for basal cell carcinoma
Application: 10/808,004 →
Methods of Improving Skin Quality
Application: 10/799,999 →
Urea Substituted Imidazoquinolines
Application: 10/780,379 →
Process for Preparing 1-Substituted, 2-Substituted 1H-Imidazo[4,5-C]Quinolin-4-Amines
Application: 10/731,826 →
Method for decreasing sebum
Application: 60/509,984 →
Process for Preparing Imidazoquinolinamines
Application: 10/624,014 →
Process for Preparing 1-Substituted, 2-Substituted 1-H-Imidazo(4,5-C)Quinolin-4-Amines
Application: 10/436,905 →